The field of stem cell therapy has exploded recently. Much excitement has been generated over growing evidence that various stem cell populations have potential to differentiate into most or all of the cell types found in the body, thus providing the first source of replacement cell and tissue therapy.
The challenge has been converting these bench-top observations into commercially feasible, and near-term clinically significant products. One of the biggest problems has been obtaining large enough numbers of functional cells for clinical use. While cell lines generated from embryonic stem cells might provide an expandable source of therapeutic cells, political and ethical debates have limited research in this area.
Adult stem cells isolated from human bone marrow or peripheral blood can provide a good alternative source of therapeutic replacement cells. Up to now, a major obstacle has been obtaining the right kind of stem cell population for tissue regeneration application in large enough numbers to produce the desired therapeutic effect.
Different companies have struggled to design culture conditions that allow the expansion of adult stem cell populations without changing their ability to differentiate fully into all cell types. To date, no company has been successful.
ALDAGEN has taken a different approach. The Company's technology is the only one able to isolate from a patient's bone marrow or other stem cell sources, a potent population of therapeutic cells including all of the stem and progenitor cell types needed for optimal cell therapy.
